@pharmazeitung.bsky.social#Tavapadon, ein selektiver Agonist der Dopaminrezeptoren 1 und 5, ist seit Kurzem in den USA zur Behandlung von Menschen mit #Parkinson zugelassen. Es kann sowohl als Monotherapie als auch als Add-on zu Levodopa eingesetzt werden.
@medchemexpress.bsky.socialThe FDA has approved AbbVie's JUVMO (#tavapadon) for adults with #ParkinsonsDisease, introducing the first and only selective D1/D5 #dopamine receptor agonist approved for the disease.
https://ow.ly/WqGT50ZW8Yj
🧪Explore Tavapadon for research use from MedChemExpress: https://ow.ly/kC6C50ZW8Yn
@longevitytech.bsky.socialAbbVie’s JUVMO (tavapadon) targets dopamine differently from older drugs and is expected in US pharmacies this month, the company says.
Link as first comment.
@newsevoce.bsky.socialEUA aprovam remédio para Parkinson que age de jeito inédito no cérebro: Tavapadon é o primeiro medicamento a ativar de forma seletiva os receptores de dopamina D1 e D5. Em estudo, aumentou em mais de uma hora por dia o tempo em que os pacientes se movimentam bem. #Parkinson #Tavapadon
@pharmaphorum.bsky.socialThe first product from #AbbVie's $8.7 billion takeover of #Cerevel two years ago – #Parkinsonsdisease therapy #tavapadon – has been approved by the #FDA.
@neurologyadvisor.bsky.socialFlexible-dose #tavapadon significantly improved motor symptoms compared with placebo among patients with early #ParkinsonDisease, although the trial’s short duration limited conclusions about long-term safety and tolerability.